Last reviewed · How we verify
BC006
BC006 is a monoclonal antibody targeting the PD-1 receptor.
BC006 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | BC006 |
|---|---|
| Sponsor | Dragonboat Biopharmaceutical Company Limited |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, BC006 prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and enhancing anti-tumor activity.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis (PHASE2)
- Microbial Enzyme Impact on Postprandial Nutrient Levels and Gastrointestinal Symptoms in Healthy Adults (NA)
- An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BC006 CI brief — competitive landscape report
- BC006 updates RSS · CI watch RSS
- Dragonboat Biopharmaceutical Company Limited portfolio CI